drugset / Trial / NCT00121615

Study of Etanercept in the Treatment of Psoriasis in Adult Subjects

NCT00121615

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The objective of the study is to describe the safety, tolerability, and efficacy of the long-term administration of etanercept in adults with psoriasis who have completed etanercept psoriasis study 20030115 or 20030117, in Canada, and are continuing in a long-term extension. Subjects from the 20030115 study will be followed for 24 months which began in Oct. 2004. Subjects in the 20030117 study will be followed for 12 months which began in mid 2005.

Timeline

Start
2004-10
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 25 mg
Subject Etanercept Protein / enzyme biologic 50 mg

Indications